EX-99.1 2 abbv-20241231nonxgaapxex991.htm EX-99.1

AbbVie Inc.

Guidance Including the Impact of Acquired IPR&D and Milestones Expense

(Unaudited)

 

(in millions, except per share data)			Quarter Ended December 31, 2024																		Full-Year Ended December 31, 2024
			Acquired IPR&D and Milestones Expense						Adjusted Diluted EPS Range												Acquired IPR&D and Milestones Expense						Adjusted Diluted EPS Range
									Low						High												Low						High
Previously announced guidance excluding Q4 2024 acquired IPR&D and milestones expense			$	—					$	2.94					$	2.98					$	1,183					$	10.90					$	10.94
Q4 2024 acquired IPR&D and milestones expense			1,574						(0.88)						(0.88)						1,574						(0.88)						(0.88)
Guidance including Q4 2024 Acquired IPR&D and milestones expense			$	1,574					$	2.06					$	2.10					$	2,757					$	10.02					$	10.06

    1